[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 904
Citations 0
Comment & Response
May 26, 2015

Mortality and Ratio of Blood Products Used in Patients With Severe Trauma—Reply

Author Affiliations
  • 1Center for Translational Injury Research, University of Texas Health Science Center, Houston
JAMA. 2015;313(20):2078-2079. doi:10.1001/jama.2015.4427

In Reply Dr Moore and colleagues raise issues regarding clinical trial end points. The 24-hour and 30-day regulatory end points commonly used are based on convenient clock and calendar periods rather than the physiology of patients with severe and multiple injuries at high risk of hemorrhagic death. Regarding potential bias in the determination of hemostasis and death due to exsanguination, these end points were prespecified by investigators as clinically relevant and operationalized to avoid bias. Each death was reviewed by the attending surgeon and then adjudicated by an external clinician blinded to group assignment.

First Page Preview View Large
First page PDF preview
First page PDF preview